Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Operating Expenses (2019 - 2025)

Karyopharm Therapeutics' Other Operating Expenses history spans 9 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 11.5% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.9 million, down 0.97%, while the annual FY2025 figure was $5.9 million, 0.97% down from the prior year.
  • Other Operating Expenses reached $1.5 million in Q4 2025 per KPTI's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.1 million in Q3 2025 to a low of $589000.0 in Q3 2021.
  • Average Other Operating Expenses over 5 years is $1.3 million, with a median of $1.3 million recorded in 2024.
  • The largest YoY upside for Other Operating Expenses was 187.37% in 2021 against a maximum downside of 99.64% in 2021.
  • A 5-year view of Other Operating Expenses shows it stood at $742000.0 in 2021, then soared by 151.75% to $1.9 million in 2022, then fell by 20.45% to $1.5 million in 2023, then decreased by 10.43% to $1.3 million in 2024, then increased by 11.5% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Operating Expenses are $1.5 million (Q4 2025), $2.1 million (Q3 2025), and $1.1 million (Q2 2025).